Dayton Clinical Oncology Program

代顿临床肿瘤学项目（代顿NCORP）：项目总结/摘要 代顿临床肿瘤学项目（以下简称“代顿NCORP”）于2010年10月15日并入。 1983年，作为一家非营利性501 c3公司，成为俄亥俄州的一员，也是最初的NCI社区之一。 临床肿瘤学项目（CCOP）。当时，一个财团协议， 代顿NCORP、代顿地区成人医院和赖特州立大学（WSU）。一个理事 成立了董事会，制定了公司细则。 凯特林医疗中心是最初的受赠组织，直到2001年，当代顿NCORP 与华盛顿州立大学分包人力资源、技术支持和财务监督。代顿 NCORP与当地一家会计师事务所签订合同，进行年度外部A-133财务审计。在 2014年，代顿临床肿瘤学项目成功获得NCI社区肿瘤学 研究计划（NCORP）社区网站五年补助金。 目前，代顿NCORP董事会由首席研究员霍华德M。恶心， M.D. John Haluschak博士，副首席研究员兼副主席， 董事会和玛丽Ontko，BSN，RN，OCN，董事会主席兼首席执行官。其他 董事代表联合医院成员。董事会每半年举行一次会议，审查预算 报告和方案活动。 54名医生，代表内科、外科、妇科肿瘤学和放射治疗，20名 由我们的成员医院资助的医院肿瘤学研究护士，以及13名办公室工作人员， 由国家癌症研究所资助组成研究小组办公室工作人员包括质量、法规、 和研究项目，沿着有研究协调员，一名药房技术员，一名行政人员， 专家和研究助理。代顿NCORP正在扩大;扬斯敦的三家医院， 东北部俄亥俄州，已经签署了一项财团协议，并正在进行的第一步，这一进程 加入代顿NCORP，其他网站也表示有兴趣加入。 代顿NCORP目前正在寻求持续的资金，通过六个赠款年期间运行8月 1，2019年至2025年7月31日。继续提供资金将使该财团继续代顿 NCORP使命通过改进治疗和预防降低癌症发病率和死亡率 通过向当地社区提供国家最先进的癌症研究。

Dayton Clinical Oncology Program (Dayton NCORP): Project Summary/Abstract The Dayton Clinical Oncology Program, hereafter referred to as “Dayton NCORP”, was incorporated in the State of Ohio in 1983 as a non-profit 501c3 corporation, and one of the original NCI Community Clinical Oncology Programs (CCOP). At that time, a consortium agreement was established between Dayton NCORP, the Dayton area adult hospitals, and Wright State University (WSU). A governing board was established and corporate bylaws were developed. Kettering Medical Center was the original grantee organization until 2001, when Dayton NCORP subcontracted with WSU for human resources, technical support, and financial oversight. Dayton NCORP contracts with a local accounting firm to conduct an annual external A-133 financial audit. In 2014, Dayton Clinical Oncology Program, was successfully awarded an NCI Community Oncology Research Program (NCORP) Community Site five-year grant. Currently, the Dayton NCORP Board of Directors is led by Principal Investigator Howard M. Gross, M.D. as Chairperson, Dr. John Haluschak, Associate Principal Investigator and Vice Chairperson of the Board, and Mary Ontko, BSN, RN, OCN, President of the Board and Chief Executive Officer. Other directors represent consortium hospital-members. The Board meets semi-annually to review budget reports and program activities. Fifty-four physicians, representing medical, surgical, gynecological oncology and radiation therapy, 20 hospital-based oncology research nurses, funded by our member hospitals, and 13 office staff, funded by the NCI grant, make up the research team. The office staff includes directors for quality, regulatory, and research projects, along with research coordinators, a pharmacy technician, an administrative specialist, and a research associate. Dayton NCORP is expanding; three hospitals in Youngstown, in northeast Ohio, have signed a Consortium Agreement and are undergoing the first steps of the process to join Dayton NCORP, and other sites have expressed interest in joining. Dayton NCORP is currently seeking continued funding through the six-grant year period running August 1, 2019 through July 31, 2025. Continued funding will allow the consortium to continue the Dayton NCORP mission To reduce cancer incidence and mortality through improved treatment and prevention by offering national state-of-the-art cancer research to the local communities.